Inherited human IFN-γ deficiency underlies mycobacterial disease.
Genetic diseases
Genetics
Immunology
Journal
The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877
Informations de publication
Date de publication:
01 06 2020
01 06 2020
Historique:
received:
04
12
2019
accepted:
04
03
2020
pubmed:
13
3
2020
medline:
3
2
2021
entrez:
13
3
2020
Statut:
ppublish
Résumé
Mendelian susceptibility to mycobacterial disease (MSMD) is characterized by a selective predisposition to clinical disease caused by the Bacille Calmette-Guérin (BCG) vaccine and environmental mycobacteria. The known genetic etiologies of MSMD are inborn errors of IFN-γ immunity due to mutations of 15 genes controlling the production of or response to IFN-γ. Since the first MSMD-causing mutations were reported in 1996, biallelic mutations in the genes encoding IFN-γ receptor 1 (IFN-γR1) and IFN-γR2 have been reported in many patients of diverse ancestries. Surprisingly, mutations of the gene encoding the IFN-γ cytokine itself have not been reported, raising the remote possibility that there might be other agonists of the IFN-γ receptor. We describe 2 Lebanese cousins with MSMD, living in Kuwait, who are both homozygous for a small deletion within the IFNG gene (c.354_357del), causing a frameshift that generates a premature stop codon (p.T119Ifs4*). The mutant allele is loss of expression and loss of function. We also show that the patients' herpesvirus Saimiri-immortalized T lymphocytes did not produce IFN-γ, a phenotype that can be rescued by retrotransduction with WT IFNG cDNA. The blood T and NK lymphocytes from these patients also failed to produce and secrete detectable amounts of IFN-γ. Finally, we show that human IFNG has evolved under stronger negative selection than IFNGR1 or IFNGR2, suggesting that it is less tolerant to heterozygous deleterious mutations than IFNGR1 or IFNGR2. This may account for the rarity of patients with autosomal-recessive, complete IFN-γ deficiency relative to patients with complete IFN-γR1 and IFN-γR2 deficiencies.
Identifiants
pubmed: 32163377
pii: 135460
doi: 10.1172/JCI135460
pmc: PMC7260033
doi:
pii:
Substances chimiques
IFNG protein, human
0
IFNGR2 protein, human
0
Receptors, Interferon
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3158-3171Subventions
Organisme : NIAID NIH HHS
ID : R37 AI095983
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001866
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000043
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI089970
Pays : United States
Références
J Exp Med. 2008 Aug 4;205(8):1729-37
pubmed: 18625743
Adv Immunol. 2007;96:41-101
pubmed: 17981204
Nat Med. 2016 Sep;22(9):994-1001
pubmed: 27525523
Hum Mol Genet. 2019 Feb 1;28(3):524
pubmed: 30329057
Hum Mutat. 2017 Oct;38(10):1286-1296
pubmed: 28744922
N Engl J Med. 1996 Dec 26;335(26):1956-61
pubmed: 8960475
Biochim Biophys Acta. 2002 Nov 11;1592(3):237-50
pubmed: 12421669
J Clin Invest. 2000 May;105(10):1429-36
pubmed: 10811850
Hum Mutat. 2011 Jun;32(6):633-42
pubmed: 21448974
Medicine (Baltimore). 2010 Nov;89(6):381-402
pubmed: 21057261
J Infect Dis. 2000 Jan;181(1):379-84
pubmed: 10608793
J Clin Immunol. 2019 Feb;39(2):127-130
pubmed: 30719685
Proc Natl Acad Sci U S A. 2019 May 21;116(21):10430-10434
pubmed: 31068474
J Exp Med. 2015 Sep 21;212(10):1641-62
pubmed: 26304966
Medicine (Baltimore). 2013 Mar;92(2):109-22
pubmed: 23429356
Nat Genet. 2005 Jul;37(7):692-700
pubmed: 15924140
Nat Methods. 2016 Feb;13(2):109-10
pubmed: 26820543
Hum Mol Genet. 2011 Apr 15;20(8):1509-23
pubmed: 21266457
Alger Medicale. 1951 Oct;55(8):1138-47
pubmed: 14894415
J immunodefic Disord. 2014 Jun 4;3:
pubmed: 25544967
Clin Dev Immunol. 2011;2011:691956
pubmed: 21234109
J Allergy Clin Immunol. 2019 Jun;143(6):2215-2226.e7
pubmed: 30578871
Adv Intern Med. 2000;45:431-52
pubmed: 10635058
Semin Immunol. 2014 Dec;26(6):454-70
pubmed: 25453225
Nucleic Acids Res. 1982 Apr 24;10(8):2487-501
pubmed: 6176945
N Engl J Med. 2011 Jul 14;365(2):127-38
pubmed: 21524210
N Engl J Med. 1996 Dec 26;335(26):1941-9
pubmed: 8960473
Lancet. 1995 Aug 26;346(8974):581
pubmed: 7658805
Nature. 2015 Jan 1;517(7532):89-93
pubmed: 25307056
Sci Immunol. 2018 Dec 21;3(30):
pubmed: 30578352
Am J Med Genet A. 2010 Mar;152A(3):622-9
pubmed: 20186794
J Biol Chem. 1995 Apr 14;270(15):8797-804
pubmed: 7721786
Nat Genet. 1999 Apr;21(4):370-8
pubmed: 10192386
Crit Rev Clin Lab Sci. 2018 May;55(3):184-204
pubmed: 29502462
PLoS Comput Biol. 2012;8(12):e1002806
pubmed: 23236270
Immunol Cell Biol. 2019 Apr;97(4):360-367
pubmed: 30264912
Science. 1998 May 29;280(5368):1435-8
pubmed: 9603733
Immunol Rev. 2015 Mar;264(1):103-20
pubmed: 25703555
Curr Protoc Immunol. 2016 Nov 1;115:7.21C.1-7.21C.12
pubmed: 27801513
Nat Immunol. 2018 Sep;19(9):973-985
pubmed: 30127434
Biochem Biophys Res Commun. 1998 Feb 4;243(1):170-6
pubmed: 9473500
Science. 1965 Jul 16;149(3681):310-1
pubmed: 17838106
Nat Genet. 2002 Jan;30(1):97-101
pubmed: 11731797
J Clin Invest. 1997 Dec 1;100(11):2658-64
pubmed: 9389728
J Immunol. 2002 Sep 1;169(5):2545-52
pubmed: 12193724
Science. 2001 Jul 13;293(5528):300-3
pubmed: 11452125
J Clin Immunol. 2014 Nov;34(8):922-7
pubmed: 25216720
J Allergy Clin Immunol. 2014 Feb;133(2):591-2
pubmed: 24220318
Clin Infect Dis. 2014 Jan;58(2):204-13
pubmed: 24186907
Blood. 2004 Oct 1;104(7):2095-101
pubmed: 15178580
Sci Immunol. 2018 Dec 21;3(30):
pubmed: 30578351
Biochem Biophys Res Commun. 1994 Sep 30;203(3):1645-54
pubmed: 7945313
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):497-501
pubmed: 8552669
J Clin Invest. 2017 Dec 1;127(12):4415-4420
pubmed: 29106381
Nat Genet. 2014 Mar;46(3):310-5
pubmed: 24487276
Hum Mol Genet. 2013 Feb 15;22(4):769-81
pubmed: 23161749
Bioinformatics. 2018 Dec 15;34(24):4307-4309
pubmed: 30535305
J Immunol. 2004 Sep 15;173(6):4000-8
pubmed: 15356149
J Exp Med. 2006 Jul 10;203(7):1745-59
pubmed: 16818673
Science. 1991 May 3;252(5006):698-702
pubmed: 1902591
Nat Immunol. 2011 Mar;12(3):213-21
pubmed: 21278736
J Clin Immunol. 2019 Oct;39(7):739-742
pubmed: 31377971
Arch Biochem Biophys. 2003 May 1;413(1):91-8
pubmed: 12706345
Lancet. 1995 Jan 14;345(8942):79-83
pubmed: 7815885
J Clin Invest. 1998 Jun 1;101(11):2364-9
pubmed: 9616207
Blood. 2013 Oct 3;122(14):2390-401
pubmed: 23963039
Lancet. 2004 Dec 11-17;364(9451):2113-21
pubmed: 15589309
Annu Rev Immunol. 2002;20:581-620
pubmed: 11861613
J Exp Med. 2018 Sep 3;215(9):2289-2310
pubmed: 30068544
J Exp Med. 2011 Dec 19;208(13):2747-59
pubmed: 22162829
Science. 1993 Mar 19;259(5102):1742-5
pubmed: 8456301
J Clin Immunol. 2014 Nov;34(8):904-9
pubmed: 25135595
EMBO J. 1982;1(8):953-8
pubmed: 6329718
Science. 2012 Sep 28;337(6102):1684-8
pubmed: 22859821
Science. 1998 May 29;280(5368):1432-5
pubmed: 9603732
Eur J Immunol. 2016 Sep;46(9):2155-61
pubmed: 27325567
J Biol Chem. 1978 Nov 10;253(21):7612-5
pubmed: 701277
Clin Immunol. 2002 Jan;102(1):25-7
pubmed: 11781064
Nature. 1982 Aug 26;298(5877):859-63
pubmed: 6180322
J Clin Invest. 1998 Dec 15;102(12):2035-40
pubmed: 9854038
Annu Rev Immunol. 1997;15:563-91
pubmed: 9143700
J Exp Med. 1983 Sep 1;158(3):670-89
pubmed: 6411853
Pediatrics. 1996 Oct;98(4 Pt 1):774-8
pubmed: 8885960
Eur J Immunol. 2004 Nov;34(11):3276-84
pubmed: 15384045
Nat Commun. 2016 Dec 23;7:13992
pubmed: 28008925
Hum Mol Genet. 2010 Feb 1;19(3):434-44
pubmed: 19880857
Science. 1993 Mar 19;259(5102):1739-42
pubmed: 8456300
Proc Natl Acad Sci U S A. 2015 Nov 3;112(44):13615-20
pubmed: 26483451
Immunity. 1995 Jul;3(1):109-17
pubmed: 7621071
J Exp Med. 2019 Aug 5;216(8):1777-1790
pubmed: 31213488
Curr Opin Allergy Clin Immunol. 2001 Dec;1(6):503-11
pubmed: 11964733